U.S. lawmakers say WHO opioid guidelines too lax

The World Health Organization’s pain care guidelines contain false claims about the safety of

Medication nonadherence common in patients with T2DM

(HealthDay)—Routine urine samples can be used to test for medication adherence in patients with

As more veterans die of opioid overdoses, study shows need to focus beyond prescriptions

A dramatic rise in opioid overdose deaths among American veterans in recent years has

Rising prescription drug costs continue to create tough choices for seniors

(HealthDay)—A solid minority of senior citizens still struggles to afford their prescription medications, a

Avelumab and axitinib approved for treatment of renal cell carcinoma

(HealthDay)—Avelumab (BAVENCIO) was approved this week for first-line treatment of advanced renal cell carcinoma

Americans’ prescription med use is declining

(HealthDay)—Bucking a longstanding upward trend, new data shows that the percentage of Americans taking

Drug overdoses in young people on the rise

In American adolescents and young adults, death rates from drug poisoning, particularly from opioids,

Researchers engineer a cost-effective treatment for neglected tropical disease

Researchers have turned a fungus into a disease-curing factory through modern genetic engineering and

Over-the-counter meds save health care system money

(HealthDay)—On average, each dollar spent on over-the-counter (OTC) medicines saves the U.S. health care

FDA warns homeopathic company about illegal product claims

(HealthDay)—Nutra Pharma Corp. has been warned about illegal marketing of unapproved homeopathic products with

Widespread and possibly risky use of herbal medicines among pregnant women in Ethiopia

A study of Ethiopian women’s use of traditional medicinal plants during pregnancy has come

Two for the price of one: Mechanistic insights lead to drug repositioning

Lung adenocarcinoma is the most common type of lung cancer. Although various targeted drugs

FDA Approves Keytruda (pembrolizumab) for the Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node(s) Following Complete Resection

KENILWORTH, N.J.–(BUSINESS WIRE) February 19, 2019 –Merck (NYSE: MRK), known as MSD outside the

Monthly buprenorphine injections effective for opioid use disorders

A newly published study suggests the long-acting buprenorphine formulation BUP-XR is more effective than

Research reveals need to ensure drug trials for anxiety are carried out on appropriate patients

University of Otago psychiatry experts are concerned some medications used to treat anxiety may

Merck Receives Breakthrough Therapy Designation from FDA for V114, the Company’s Investigational 15-Valent Conjugate Vaccine for the Prevention of Invasive Pneumococcal Disease, in Infants, Children, and Adolescents

KENILWORTH, N.J.–(BUSINESS WIRE) January 30, 2019 –Merck (NYSE: MRK), known as MSD outside of

Advances in the study of drugs to combat cognitive impairment in schizophrenia

A study by the UPV/EHU has assessed whether drugs used to delay cognitive deterioration

GPs prescribe more opioids for pain in poor Northern areas, study reveals

English patients living in poorer areas are likely to be prescribed more opioids by

The opioid crisis: What we should learn from the AIDS epidemic

There are important lessons to be learned from the successes and failures of the

FDA Approves ProAir Digihaler

JERUSALEM–(BUSINESS WIRE)–Dec 21, 2018–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that

FDA Approves Motegrity

Cambridge, Mass. – December 17, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) has

Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome

NEW YORK, Dec. 06, 2018 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical

Government investigation finds flaws in FDA’s orphan drug program

The Food and Drug Administration has failed to ensure that drugs given prized rare-disease

Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia

DUBLIN, Nov. 29, 2018 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced positive topline

FDA Approves Gamifant

November 20, 2018 — The U.S. Food and Drug Administration today approved Gamifant (emapalumab)

Epinephrine personal autoinjectors cost-effective at $24

(HealthDay)—In a simulation of children with peanut allergy, epinephrine personal autoinjectors are cost-effective at

Clementia Announces Plan to Submit a New Drug Application for Palovarotene for the Treatment of FOP Based on Positive Phase 2 Results

MONTREAL, Oct. 23, 2018 (GLOBE NEWSWIRE) — Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage

US health chief says overdose deaths beginning to level off

The number of U.S. drug overdose deaths has begun to level off after years

FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Asthma

PARIS and TARRYTOWN, N.Y., Oct. 19, 2018 /PRNewswire/ — Sanofi (EURONEXT: SAN) (NYSE: SNY)

Common use of antipsychotics shown ineffective for delirium in intensive care patients

Critically ill patients in intensive care units (ICUs) did not benefit from two antipsychotic